New antibody drug aims to tame MS Flare-Ups

NCT ID NCT04879628

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study tested whether an investigational antibody drug called SAR441344 can reduce new areas of inflammation (lesions) in the brain for people with relapsing forms of multiple sclerosis (MS). About 129 participants received either the drug or a placebo to compare effectiveness and safety. The main goal was to see if the drug lowers the number of new brain lesions seen on MRI scans over a 12-week period.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Center for Neurology and Spine- Site Number : 8400007

Phoenix, Arizona, 85032, United States
Investigational Site Number : 1000001

Sofia, 1407, Bulgaria
Investigational Site Number : 1000002

Pleven, 5809, Bulgaria
Investigational Site Number : 1000003

Sofia, 1113, Bulgaria
Investigational Site Number : 1240001

Gatineau, Quebec, J8Y 1W2, Canada
Investigational Site Number : 2030001

Jihlava, 58633, Czechia
Investigational Site Number : 2030002

Hradec Králové, 50005, Czechia
Investigational Site Number : 2030003

Brno, 65691, Czechia
Investigational Site Number : 2030004

Teplice, 415 29, Czechia
Investigational Site Number : 2030005

Ostrava - Poruba, 70852, Czechia
Investigational Site Number : 2500006

Calais, 62107, France
Investigational Site Number : 2760004

Münster, 48149, Germany
Investigational Site Number : 2760012

Leipzig, 04103, Germany
Investigational Site Number : 6430001

Moscow, 127015, Russia
Investigational Site Number : 6430002

Kazan', 420032, Russia
Investigational Site Number : 6430003

Saint Petersburg, 194044, Russia
Investigational Site Number : 6430004

Saint Petersburg, 197110, Russia
Investigational Site Number : 6430005

Saint Petersburg, 197022, Russia
Investigational Site Number : 6430006

Moscow, 117997, Russia
Investigational Site Number : 6430007

Moscow, 117556, Russia
Investigational Site Number : 6430008

Tyumen, 625000, Russia
Investigational Site Number : 7240002

Vigo, 36312, Spain
Investigational Site Number : 7240004

Barcelona, Barcelona [Barcelona], 08035, Spain
Investigational Site Number : 7920001

İzmit, 41380, Turkey (Türkiye)
Investigational Site Number : 7920002

Mersin, 33070, Turkey (Türkiye)
Investigational Site Number : 7920003

Istanbul, 34265, Turkey (Türkiye)
Investigational Site Number : 7920004

Eskişehir, 26040, Turkey (Türkiye)
Investigational Site Number : 8040002

Kyiv, 01135, Ukraine
Investigational Site Number : 8040003

Odesa, 65025, Ukraine
Investigational Site Number : 8040004

Lviv, 79013, Ukraine
Investigational Site Number : 8040005

Vinnytsia, 21001, Ukraine
Investigational Site Number : 8040006

Dnipro, 49089, Ukraine
Investigational Site Number : 8040008

Ivano-Frankivsk, 76493, Ukraine
Investigational Site Number : 8040010

Dnipro, 49005, Ukraine
Medical College of Wisconsin- Site Number : 8400006

Milwaukee, Wisconsin, 53226, United States
The Neurological Institute Site Number : 8400004

Charlotte, North Carolina, 28204, United States
University of South Florida Site Number : 8400001

Tampa, Florida, 33612, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS